Loading...

柏安診所-提供您長期穩定及先進的醫療照顧
Posted On 14 2 月, 2021 / By / Posted in 臨床指引

Osteoporosis in CKD G4-G5D

Evenepoel P, Cunningham J, Ferrari S, et al. European Consensus Statement on the diagnosis and management of osteoporosis in chronic kidney disease stages G4-G5D. Nephrol Dial Transplant 2021;36:42-59. 診斷不變:Spine或hip的DXA T score <

read more
Posted On 27 1 月, 2021 / By / Posted in RCT閱讀

SGLT2i

Sotagliflozin 仿單 [EU-202010] [SCORED] N=10,548 (A1C>7%, eGFR 25-60, ⊕CV risk), 200→400mg/d vs placebo, 1º outcome (MACE/CV death/HF住院) HR 0.74 (0.63-0.88) at median 14m [Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease.

read more
Posted On / By / Posted in RCT閱讀

RCT for CKD (List)

[DAPA-CKD] N=4094 (eGFR 25-75, UACR 200~2000, 32.5% w/o DM, 14.5% G4 CKD); Dapa 10mg/d vs placebo; 1º outcome (GFR↑2x, ESRD, CV/renal death) HR 0.61 (0.51-0.72; P<0.001), median 2.4yr [N Engl J Med.

read more
Posted On / By / Posted in RCT閱讀

Dapagliflozin in Patients with Chronic Kidney Disease

Heerspink HJL, Stefánsson BV, Correa-Rotter R, et al. Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2020;383(15):1436-1446. 7億人有CKD 過去證實能減緩腎功能惡化的藥, 為ACEi及ARB, 多數是做在T2DM族群 SGLT2i在T2DM族群證實可改善心腎預後 (CREDENCE – canagliflozin, NEJM 2019), 機轉可能不只是降糖本身, 還包含natriuresis及glucose-induced

read more
Posted On 26 1 月, 2021 / By / Posted in Diabetic Nephropathy

CPG for DM in CKD (KDIGO 2020)

Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney Int. 2020;98(4S):S1–S115. Reference Keys CKD is defined as abnormalities of kidney structure

read more